GT Biopharma, Inc. (GTBP) Market Cap & Valuation Ratios
GT Biopharma, Inc. (GTBP) has a market cap of $9.9M, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
GTBPGT Biopharma, Inc.Follow GTBP — free
—
Price chart with a free account
- Market cap
- 9.9M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 12 Nov, in 19 days
Peers
drug manufacturers - general · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| GTBP | 0.0 | — | — | — | — | — | — | — |
| ABEO | 0.3 | — | 4.7 | — | — | — | -328% | -157% |
| LYEL | 0.2 | — | 963.0 | — | — | -55% | — | -142% |
| EVMN | 0.2 | — | — | — | — | +86% | — | -47% |
| FHTX | 0.1 | — | 1.4 | — | — | +52% | -198% | — |
| YARW | 0.1 | — | 59.2 | — | — | +1% | — | — |
| IBO | 0.0 | — | 878.5 | — | -1.7% | — | — | -47% |
| RMTI | 0.0 | — | 0.4 | — | 5.5% | -21% | -7% | -15% |
| CMMB | 0.0 | 1.1 | — | — | — | — | — | — |
| LGVN | 0.0 | — | — | — | — | -43% | — | — |
| ENLV | 0.0 | — | — | — | — | — | — | -0.6% |
| Median of these 10 | 1.1 | 31.9 | — | 1.9% | -10% | -198% | -47% |
.
Growth vs. price
each dot a company · hover or tap for valuesGT Biopharma, Inc. — questions
- What is GT Biopharma, Inc.'s market cap?
- $9.9M.
Every figure on this page comes from GT Biopharma, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.